pdf   xlsx method abbreviations

metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), ... , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.90 [0.79, 1.03]< 10%3 studies (3/-)93.9 %lownot evaluable highcrucial-
progression or deaths (PFS) 0.63 [0.42, 0.95]< 186%3 studies (3/-)98.6 %some concernnot evaluable moderateimportant-
objective responses (ORR) 1.46 [0.95, 2.26]> 10%2 studies (2/-)95.6 %some concernnot evaluable moderatenon important-

safety endpoints 00

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.